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Abstract
Background: The contribution of aberrant DNA methylation in silencing of tumor suppressor genes (TSGs) and microRNAs
has been investigated. Since these epigenetic alterations are reversible, it became of interest to determine the effects of the
5-aza-29-deoxycytidine (DAC) demethylation therapy in breast cancer at different molecular levels.
Methods and Findings: Here we investigate a synoptic model to predict complete DAC treatment effects at the level of
genes, microRNAs and proteins for several human breast cancer lines. The present study assessed an effective treatment
dosage based on the cell viability, cytotoxicity, apoptosis and methylation assays for the investigated cell lines. A highly
aggressive and a non-aggressive cell line were investigated using omics approaches such as MALDI-TOF MS, mRNA- and
microRNA expression arrays, 2-D gel electrophoresis and LC-MS-MS. Complete molecular profiles including the biological
interaction and possible early and late systematic stable or transient effects of the methylation inhibition were determined.
Beside the activation of several epigenetically suppressed TSGs, we also showed significant dysregulation of some
important oncogenes, oncomiRs and oncosuppressors miRNAs as well as drug tolerance genes/miRNAs/proteins.
Conclusions: In the present study, the results denote some new molecular DAC targets and pathways based on the
chemical modification of DNA methylation in breast cancer. The outlined approach might prove to be useful as an
epigenetic treatment model also for other human solid tumors in the management of cancer patients.
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Introduction
Aberrant DNA methylation patterns are associated with various
human diseases [1] including cancer development [2]. Hyper-
methylation of human tumor suppressor genes (TSGs) leads to
transcriptional inactivation followed by the gene silencing and
carcinogenesis [3].
It was also discovered that microRNAs (miRNAs), endogenous
non-coding RNAs with 19–25 nucleotides in size, play important
roles in various cellular processes including cellular growth,
differentiation and apoptosis [4] that contribute to cancer
development and progression [5]. Moreover, emerging studies
reported that miRNAs are involved in promoter DNA methylation
changes [6]. DNA sequences of encoding miRNAs were also
found to be a target of aberrant DNA methylation as well as
protein-coding genes [7].
Genetic changes such as mutation or deletion are resulting in
permanent loss of gene expression while epigenetic changes are
often reversible [8,9]. Reversal hypermethylation of silenced TSGs
or miRNAs is increasingly being targeted for cancer therapy and
prevention [10,11]. Moreover, these approaches are particularly
appealing because DNA methylation inhibitors are considerably
less toxic in non-cancerous tissues compared to other anti-cancer
drugs [12].
The 5-aza-29-deoxycytidine (decitabine; DAC; Dacogen, Eisai,
Inc.), has recently been approved by the Food and Drug
Administration (FDA) for the treatment of patients with
Myelodysplastic Syndromes (MDS) and leukemia [13,14]. Since
DAC is one of the nucleotide analogs that is activated via
phosphorylation by cellular deoxcytidine kinase and is incorpo-
rated into the DNA, the result of this process is thought to lead to
the depletion of methyltransferase activity and to demethylation
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27355of DNA [15]. Several strategies have been applied to optimize or
enhance the activity of DAC as a promising agent for cancer
therapy [16].
Pan-omics approaches at multiple molecular levels, after DAC
treatment for solid tumors, are promising in opening new
mechanistic insights in this area of cancer biology. These
approaches enable to synoptically probe the transcriptome and
the proteome to epigenetic changes in order to understand the
complete phenotype of treated cells. Therefore we used DAC in
this study as a tool to predict early and late effects of DAC on
different breast cancer cell lines using pan-omics approaches.
Materials and Methods
An optimal treatment dose screening for DAC was established
based on the viability, toxicity, apoptosis and methylation alterations
of candidate TSGs, for six breast cancer cell lines (MDA-
MB231[17], MCF-7[18], HS578T[19], BT549[20], T47D[21]
and SKBR3[22]) and a breast epithelial cell line (HB2)[23] as a
control.
After finding an optimal dose, three selected cell lines (HB2,
MDA-MB231 and SKBR3) were treated with the optimal dose of
DAC (10
2 nM, ,5 days), then cells were cultured up to 10
passages at ‘‘drug holiday’’ condition. Simultaneous extraction of
DNA, RNA, miRNA and proteins was performed according to a
previously published protocols [24]. 3-dimentional omics analysis
including gene expression, microRNA expression and proteomics
analysis was assessed before treatment, after almost 5 days of
continuous treatment and at five point follow-ups (1
st,3
rd,5
th,7
th
and 10
th passages) at ‘‘drug holiday’’ condition. Differentially
expressed genes, miRNAs and proteins, after treatment and at
follow-up passages, were measured relative to the untreated
samples. Microarray expression profiling of mRNAs and miRNAs
were conducted using the Human Genome 133 Plus 2.0
GeneChips and Affymetrix GeneChipR miRNA array v1.0,
respectively using protocols recommended by the manufacturer
(Affymetrix). In order to avoid random fluctuations in mRNAs/
miRNAs expression, after log transformation and Robust Multi-
array Analysis (RMA) normalization, differentially expressed
mRNAs/miRNAs were defined by applying three stringent
filtering criteria (mean intensity greater than six, fold change
greater than two and ANOVA test set to P,0.05) using Partek
Genomics Suite software v6.5 (Partek Incorporated, Missouri,
USA). All mRNA microarray data compiled for this study is made
publicly available on GEO (http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE28968 and miRNA microarray data
under accession number GSE28969. To validate the microarray
findings, quantitative real-time (qRT) PCR was performed for 28
candidate genes and 15 candidate miRNAs.
The proteomic profile was investigated using two-dimensional
gel electrophoresis (2DE) based on the previously published
method [24] and analyzed with Progenesis SameSpot software (v
4.0, NonLinear Dynamics, UK). The samples variables were
expressed as mean of each replicate (SE or percentages, and were
statistically analyzed by ANOVA). The cutoff level for a
differentially expressed protein was defined based on an ANOVA
test at significance of P,0.05 using the SameSpots software
considering a minimum of 1.5-fold change (normalized volume).
The protein spots of interest were excised from the gels and
analyzed by capillary liquid chromatography tandem MS (LC-
MS-MS). Protein identification was done using TurboSequest
software [25]. Gene networks and canonical pathways including
protein-protein interactions as well as genes-miRNAs interactions
were identified using the Pathway StudioH software and ResNetH
(Mammal) database). The complete materials and method is
presented in Dataset S1.
Results and Discussion
5-aza-29-deoxycytidine (DAC) optimal dose-range finding
In the present study, we have first identified the optimal,
effective dosage of DAC by investigating the impact of
concentrations in a range of 10
1 to 10
4 nM on seven different
breast cell lines (six breast cancers and a control cell line) based on
the cell viability, cytotoxicity, apoptosis and DNA methylation.
Quantification of cell viability, cytotoxicity and apoptosis
The MultiTox-Glo Multiplex Cytotoxicity assay measured the
relative number of live and dead cells in cell populations after
treatment with increasing doses of DAC and could thus determine
cell viability and cytotoxicity (Fig. 1a, b). Increasing the
concentration of the DAC (ranging from 10
1 to 10
4 nM) elevates
the cytotoxicity and reduces the ratio of the cell viability in all cell
lines. The results of these two measurements, cell viability and
cytotoxicity, are inversely correlated (as expected). Two concen-
trations, 10
1 and 10
2 nM DAC, showed viability higher than at
EC50 for all studied cell lines and they revealed lower cytotoxicity
compared to the other concentrations.
Two cellular caspases (caspase-3 and caspase-7) play a crucial
role in apoptosis and are activated in a sequential cascade of
cleavages from their inactive forms. To investigate the extent of
apoptosis after exposure to different concentration of DAC, the
enzymatic activity of caspase-3/7 was measured (Fig. 1c). These
cell death markers showed a dose dependent behavior; by
increasing the DAC concentration the caspase-3/7 activities in
all seven studied cell lines were elevated (Fig. 1c). The mean
protease activities in the cells treated with 10
3 and 10
4 nM of drug
were significantly higher than the lower dosages (P=0.001) while
the mean activities of the caspase-3/7 were similar for both 10
1
and 10
2 nM concentrations of DAC.
Quantitative methylation profiling of breast cancer
candidate genes
Based on our previous study where we assessed the methylation
status of more than 42,528 CpG sites in 22 different genes in
cancerous breast tissues versus matched normal tissues [26], we
selected six hypermethylated TSGs (BMP6, BRCA1, CST6,
CDKN2A, CDKN1A and TIMP3) to assess the effective DAC dose
range. We analyzed the methylation proportion of these six breast
cancer candidate TSGs in all seven cell lines before and after
treatment at increasing doses. For all studied genes one amplicon
containing CpG rich islands (number of CpG sites higher than 20)
was analyzed (Table 1). In total, we assessed six amplicons,
containing 171 CpG sites per sample (total of 2,394 sites in all
analyzed samples) (Table 1; Fig. 1d). The mean methylation
quantity of the informative CpG sites per each gene was used to
assess the methylation proportion of the candidate genes (Fig. 1d).
DNA methylation proportion of these six studied genes were
significantly decreased for all applied concentrations in the studied
cell lines (P,0.01) (Fig. 1d). There were no significant differences
on the extent of demethylation induced by DAC at concentrations
of 10
2,1 0
3 and 10
4 nM, whereas hypomethylation of DNA was
significantly more than the lowest treatment dosage (10
1 nM)
(Fig. 1e). This data suggests that 10
2,1 0
3 and 10
4 nM dosages of
DAC have more effective demethylation activity by significantly
reducing the methylation proportion in the treated cells.
Based on the results obtained from studies of the cell viability,
cytotoxicity, apoptosis and DNA methylation profiling, the
Pan-Omics Investigation of Demethylation Treatment
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27355Figure 1. Dose response screening within six breast cancer cell lines (MCF7, MDA-MB231, T47D, SKBR3, HS578T and BT549) and an
epithelial breast cell line (HB2) as a control. a-b) Multiplex quantification of the cell viability and cytotoxicity protease activities upon
demethylation treatment with DAC (digitonin treated cells were considered as a cell death control). c) Quantification of caspase-3 and caspase-7
activities as a measure of apoptosis. d-e) Methylation profiling of six candidate tumor suppressor genes (red clusters indicate 0% methylated, yellow
clusters indicate 100% methylated, color gradient between red and yellow indicates methylation ranging from 0-100, and black clusters indicate not
analyzed CpG sites).
doi:10.1371/journal.pone.0027355.g001
Table 1. High-throughput methylation analysis of CpG sites per amplicon for the 10 candidate genes.
Genes Amplicon size (bp)
Total No. of CpG
sites in the amplicon
No. of analyzed CpG
sites in the amplicon No. of analyzed CpG sites per amplicons
Single Composite
BMP6 397 37 30 11 19
BRCA1 413 30 15 10 5
CST6 445 49 27 15 12
CDKN2A 580 62 36 13 23
CDKN1A 419 30 19 10 9
TIMP3 441 51 44 11 33
The in silico digestion was performed for T-cleavage assay. The percentage of total CpG sites in the amplicon is divided into single sites (single CpG sites) and composite
sites (two or more adjacent CpG sites fall within one fragment, or when fragment masses are overlapping).
doi:10.1371/journal.pone.0027355.t001
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2 nM of DAC was identified to be the most
favorable because of the less cytotoxicity and good efficiency in
demethylation of DNA. This dose of DAC was chosen for the
further study on the early and late effects of the treatment using
pan-omics assays for the MDA-MB231 (highly aggressive) and
SKBR3 (non-aggressive) cell lines together with HB2 as a control
cell line. The terms ‘‘aggressive’’ and ‘‘non-aggressive’’ cell lines
refer to the in vitro phenotype of the cell lines as indicated by a
previously published paper [27].
MRNA expression profiling
Gene expression analysis using microarray chips was assessed
before treatment, after ,5 days of treatment and at five follow-up
passages at ‘‘drug holiday’’ condition. Dysregulated genes in at
least in one of the analyzed passages of each cell line were
considered as ‘‘union genes’’. The common up/down-regulated
genes in different cell lines were considered as ‘‘intersection
genes’’. Annotated lists were created for the total of 991 union
genes for HB2, 431 union genes for MDA-MB231 and 2406 union
genes for SKBR3 cell line (P,0.05, .2 fold change; Fig. 2-a1;
Dataset S2 & S5). All of the significant dysregulated union or
intersection genes within three analyzed cell lines were subjected
to the pathway analysis in order to establish their possible role in
breast neoplasms or metastasis. In parallel, K-means cluster
analysis of three studied cell lines was assessed based on the
Euclidean distances in order to find differences in gene expression
profiles within treatment passages, while the variance provided the
measure of the cluster sizes. (Dataset S2).
The expression profile of 21 candidate genes using qRT-PCR
technically confirmed the results of the expression array results
and also demonstrated the reliability and reproducibility of the
assay using the appropriate gene identifiers [28] with the high
stringency criteria as a noise filter [29].
To interpret the significance of the study, we focused on
intersection genes within the two breast cancer cell lines and also
on the intersection genes within all three studied cell lines. Besides
that, expression profiles of known tumor suppressor genes and
oncogenes were investigated based on the union lists for each cell
line.
Intersection genes within cancer cell lines. In total, 105
intersection genes were differentially expressed in MDA-MB231
and SKBR3 cell lines (Fig. 2-a5). The gene set analysis revealed
the involvement of these genes in multicellular organismal
processes, especially those that are pertinent to the generation
and maintenance of rhythms in the physiology of the cells
(rhythmic process) (Fig. 2-a6). Pathway analyses showed that 36
out of 105 intersection genes are linked to breast neoplasms or
metastasis and most of the significantly altered gene expressions in
this category can potentially trigger cell proliferations (Fig. 2-a7).
As an example, CXCL3 (a small cytokine belonging to the CXC
chemokine family that is also known as GRO3 oncogene) was up-
regulated after treatment in both cancer cell lines, while JUP (a
proliferation and oncogenesis marker) was up-regulated in MDA-
MB231 and down-regulated in SKBR3 (Table 2).
Intersection genes within all three cell lines. There were
78 intersection genes which were differentially expressed in all
three cell lines (treated and follow up passages in comparison to
untreated for each cell line respectively) (Fig. 2-a2; Dataset S2).
Based on the gene set analysis, these genes were mostly involved in
developmental, immune system processes and response to stimulus
(Fig. 2-a3). Pathway analysis showed that 30 out of 78 intersection
genes have roles in breast neoplasms, metastasis and/or cell
proliferation (Fig. 2-a4). For example, CDKN1A (P21) upon
treatment was significantly up-regulated in all three cell lines.
This is of some importance, since CDKN1A (P21) plays a
regulatory role in DNA replication, DNA damage repair and
has strong tumor suppressor activity. GJA1 (CX43) was up-
regulated in HB2 while down-regulated in MDA-MB231 and
SKBR3. This is an important finding since GJA1 is a TSG which
is associated with suppression of metastasis [30]. One explanation
for GJA1 down-regulation might be strong activation of IL8 in
cancerous cell lines that has been also reported previously as a
suppressor of GJA1 [31]. VEGFR was over-expressed in SKBR3
and HB2. This gene was down-regulated in the MDA-MB231.
Since the VEGFR gene is augmenting the cell proliferation and
oncogenesis, it can play an oncogenic role in carcinogenesis [32].
IL6 was very strongly expressed in all passages of three studied cell
lines as both early and late effect of DAC treatment. IL6 is a
multifunctional regulator of immune and inflammatory responses,
and an increase of its expression has been detected in multiple
epithelial tumors including breast cancer [33]. IL6 is involved in
the regulation of the cell proliferation, survival, and metabolism.
Additionally, high expression level of IL6 is correlated with a poor
clinical prognosis which can reflect its oncogenic role [34].
However, the involvement of IL6 in cancer is still controversial, as
dichotomous roles for IL6 in both tumor-promoting and -
suppressive activities have been reported [35].
Gene ontology (GO) enrichment analysis. The GO
enrichment analysis was assessed for three cell lines based on the
list of significantly expressed union genes in order to group them in
the functional hierarchy (Fig. 3a). The enrichment scores were
calculated using a chi-square test comparing the proportion of the
gene list in a group to the proportion of the background in the
group. Forest plot analysis showed up/down-regulated genes
according to their ontology enrichment scores in each cell line,
respectively (Fig. 3b).
Differentially expressed TSGs after DAC treatment. It is
known that TSGs are hypermethylated in different tumor types as
an early phenomenon during carcinogenesis [1,36]. In the present
study, expression status of well-known TSGs was analyzed after
treatment and follow-up passages (Dataset S2). Up-regulation of
epigenetically silenced TSGs is considered as a positive effect of
DAC treatment. Several TSGs (e.g. CDKN1A, PTEN, CST6
BRCA1 and RASSF1) were differentially expressed after treatment
(Table 2). In HB2 cell line, most of the up/down-regulated TSGs
were changed within late passages after treatment. Contrary to
this, up-regulation of several TSGs in cancer cell lines was
detected in early passages and remained stable till late passages
(Table 2).
The CDKN1A (P21) gene showed significant hypomethylation
and activation in all three studied cell lines. CDKN1A was
previously reported as a hypermethylated TSG in breast cancerous
tissue [26]. PTEN is an essential component of TP53 gene that
regulates p53 function through keeping Akt inactive and making
Mdm2 incapable of translocation into the cell nucleus [37,38].
Recently, we showed significant hypermethylation of PTEN gene
in breast cancer patients lacking TP53 mutations [39]. The
epigenetic silencing of lysosomal cysteine protease inhibitor
cystatin 6 (CST6) is more frequently observed in metastatic lesions
than in primary cancers [40]. Our previous study revealed CST6
to be significantly hypermethylated in breast tumors as compared
to the matched normal tissue [26]. CST6 was significantly
reactivated after treatment in MDA-MB231. Two important
TSGs, BRCA1 and RASSF1, which were hypermethylated in breast
tumors, [26] were significantly up-regulated in SKBR3.
Differentially expressed oncogenes after DAC
treatment. It has been reported that some oncogenes are
epigenetically hypomethylated and activated in human cancers
Pan-Omics Investigation of Demethylation Treatment
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after treatment and during follow-up passages (Dataset S2). Over-
expression of oncogenes might be a negative feature of the
treatment with DAC, while down-regulation of oncogenes could
consider as positive feature of the treatment. Oncogenes such as
RAB family genes, ETSA, CXCL1, CXCL2, CXCL3, ERBB2, MAFF,
MERTK, MYC and PDGFB were differentially expressed after
treatment (Table 2). For example, CXCL1 and CXCL2 are two
inflammatory cytokines that have a role in cell growth,
proliferation, angiogenesis and in diminishing the apoptosis;
additionally they have an oncogenic role in carcinogenesis.
Furthermore, depletion of CXCL1 and CXCL2 expressions can
inhibit metastasis [41]. In total, the dysregulation of most
important oncogenes within the analyzed passages of three cell
lines could be detected in both early and late passages after
treatment (Table 2).
Figure 2. Gene and micoRNA expression matrix. A) Gene expression of HB2, MDA-MB231 and SKBR3 cell lines. a1) The total number of
significant up/down-regulated genes within three analyzed cell lines. a2) Expression profiles of 78 intersection genes among all three cell lines as
non-cancer specific changes. a3) Gene set analysis of 78 intersection genes. a4) Pathway analysis of 30 out of 78 genes that are linked to breast
neoplasms, metastasis and/or cell proliferation. a5) Expression profiles of 105 intersection genes between MDA-MB231 and SKBR3 as cancer specific
changes. a6) Gene set analysis of 105 intersection genes. a7) Pathway analysis of 36 out of 105 genes that are linked to breast neoplasms, metastasis
and or cell proliferation. B) MicroRNA expression of HB2, MDA-MB231 and SKBR3 cell lines. b1) The total number of significant up/down-regulated
miRNAs within three analyzed cell lines. b2) Expression profiles of 23 intersection miRNAs among all three analyzed cell lines as non-cancer specific
changes. b3) Pathway analysis of 10 out of 23 miRNAs that are linked to breast neoplasms, metastasis and/or cell proliferation. b4) Expression profiles
of 8 intersection miRNAs between MDA-MB231 and SKBR3 as cancer specific changes. b5) Pathway analysis of all 8 miRNAs as cancer specific changes
that are linked to breast neoplasms, metastasis and or cell proliferation.
doi:10.1371/journal.pone.0027355.g002
Pan-Omics Investigation of Demethylation Treatment
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To seek specific miRNA profile after treatment with DAC, the
expression analysis was assessed before treatment, after ,5 days of
treatment and at five follow-up passages at ‘‘drug holiday’’
condition. Annotated lists were created of the 74, 83 and 59
miRNAs which were differentially dysregulated (P,0.05, .2 fold
change) in HB2, MDA-MB231 and SKBR3 cell lines, respectively
(Fig. 2-b1; Dataset S3 & 5). All of the significant dysregulated
union or intersection miRNAs within three cell lines were
introduced to the pathway analysis software to find their possible
Table 2. Differentially expressed well-known cancer and/or drug tolerance related TSGs, oncogenes, miRNAs and proteins after
DAC treatment in breast cancer.
3D omics
Cancer related
genes/miRNAs/proteins Up-regulated Down-regulated
HB2 MDA-MB231 SKBR3 HB2 MDA-MB231 SKBR3
Gene
expression *
Tumor suppressor
genes
CDKN1A [EL]
GJA1 (CX43) [L]
CDKN1A [E]
CST6 [E]
PDCD4 [EL]
CDKN1A [E]
BRCA1 [L]
FLCN [E]
RASSF1 [E]
DLGAP5 [L]
FAT3 [EL]
PTEN [L]
GJA1 (CX43) [L] GJA1 (CX43) [EL]
CADM1 [EL]
CDKN1B [EL]
ING4 [EL]
STEAP3 [EL]
PDCD4 [EL]
Oncogenes CXCL1 [EL]
CXCL2 [L]
ETS1 [L]
ETV7 [E]
LCN2 [L]
MAFF [EL]
MAP3K8 [EL]
PDGFB [L]
RAB33B [L]
CXCL1 [EL]
CXCL2 [EL]
CXCL3 [EL]
JUP [E]
LCN2 [EL]
RAB31 [EL]
BRAF [E]
CXCL2 [EL]
CXCL3 [E]
KLF6 [EL]
LCN2 [E]
MYC [EL]
RAB15 [L] MERTK [E]
CXCR4 [EL]
ERBB2 [E]
JUP [L]
VAV1 [EL]
Drug tolerance
related genes
FGF2 [L]
IL6 [EL]
MDK [E]
TNFSF10 [EL]
VEGFA [L]
CSF2 [EL]
IL6 [EL]
FGF2 [E]
IL6 [EL]
MDK [E]
RAD51 [EL]
SERPINB5 [EL]
SFN [EL]
SERPINB5 [L] COL1A1 [EL]
VEGFA [E]
COL18A1 [EL]
ERBB2 [E]
TGFB1 [E]
TNFSF10 [E]
VEGFA [L]
MiRNA
expression **
Tumor suppressor
(oncosuppressor)
miRNAs
miR-155 [EL]
miR-126 [EL]
miR-193b [EL] miR-155 [EL]
miR-193b [E]
miR-125b [EL]
miR-27b [EL]
miR-210 [L]
miR-15a [EL]
miR-155 [EL]
miR-27b [EL]
miR-210 [E]
miR-15a [L]
let-7f [L]
let-7g [L]
let-7i [E]
miR-125a [E]
miR-125b [E]
miR-126 [L]
miR-27b [EL]
miR-210 [EL]
miR-15a [E]
let-7f [EL]
let-7g [EL]
let-7i [EL]
OncomiRs miR-494 [E]
miR-378 [L]
miR-494 [E]
miR-378 [E]
miR-27a [EL]
miR-106b [EL]
miR-130a [L]
miR-378 [EL]
miR-27a [L]
miR-106b [L]
miR-21 [EL]
miR-24-2 [E]
miR-130a [L]
miR-27a [EL]
miR-106b [EL]
miR-21 [L]
miR-24-2 [EL]
Drug tolerance
related miRNAs
miR-638 [EL]
miR-768 [EL]
miR-638 [EL]
miR-34a [E]
miR-638 [EL]
miR-768 [EL]
miR-424 [E]
miR-28 [E]
miR-181a [L]
miR-27b [EL]
miR-28 [L]
miR-181a [L]
miR-27b [EL]
miR-21 [EL]
let-7i [E]
miR-768 [L]
miR-28 [EL]
miR-181a [E]
miR-27b [EL]
miR-21 [L]
let-7i [EL]
miR-17 [L]
Protein
expression ***
Proteins related to
cell proliferation,
neoplasms and
angiogenesis
Arhgdib [E]
Anxa2 [E]
Tgf [E]
Gstm2 [EL]
Lgals7 [EL]
Pebp1 [EL]
Sod2 [EL]
Cbx1 [EL] Bat1 [EL]
Pdia6 [EL]
Rbbp7 [L]
Ywhab [EL]
Proteins related to
cell invasion and
metastasis
P4hb [E] Arhgdia [EL]
Pebp1 [EL]
Sod2 [EL]
Pdia6 [EL]
Ywhaz [EL]
Drug tolerance
related proteins
P4hb [E] Arhgdia [EL]
Sod2 [EL]
Glo1 [EL] Pdia6 [EL]
The complete data include both early and late up- and down-regulations, P values and fold changes are presented in supplementary data.
*Dataset S2 & 5;
**Dataset S3 & 5;
***Dataset S4.
[E]: Early stage change (change after treatment and within passages 1 & 3); [L]: Late stage change (change within passages 5, 7 & 10);
[EL] Early and late change (change within passages 1-10).
doi:10.1371/journal.pone.0027355.t002
Pan-Omics Investigation of Demethylation Treatment
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cluster analysis of three studied cell lines was performed to find
differences in miRNA expression profiles within treatment
passages (Dataset S3).
For each cell line, expression profile of intersection and union
miRNAs within the passages, and their biological relevance are
presented in Dataset S3. To interpret the miRNA signatures, we
focused on the intersection miRNAs within two breast cancer cell
lines, the intersection miRNAs within all three studied cell lines
and also differentially expressed oncosuppressors and oncomiRs
based on the union lists for each cell line.
Intersection miRNAs within cancer cell lines. We
detected eight intersection miRNAs (miR-21, -24-2, -494, -193b,
-181, let-7f, let-7g and let-7i) which were differentially expressed in
two cancer cell lines (Fig. 2-b4; Table 2). The pathway analysis
revealed that all eight miRNAs have a role in breast neoplasms,
metastasis and cell proliferation (Fig. 2-b5).
Intersection miRNAs within all three cell lines. In total
23 intersection miRNAs were differentially expressed in all three
studied cell lines (Fig. 2-b2). Pathway analysis showed that 10 out
of 23 miRNAs (miR-106b, -126, -130a, -155, 15a, -210, -27a, -
27b, -342 and -378) have roles in breast neoplasms, metastasis and
or cell proliferation (Fig. 2-b3).
Differentially expressed oncosuppressor and oncomiRs
after DAC treatment. Numerous reports demonstrated that
miRNAs contribute to the development and progression of cancer
by acting as oncogenes or tumor suppressor genes [4,42]. Several
oncosuppressor miRNAs showed significant up/down-regulation
after DAC treatment but the dysregulation of the most important
ones or miRNAs were detected in both early and late passages
after treatment (Table 2). This finding highlights the strong effects
of the treatment on oncosuppressor miRNAs which were stable for
several passages at ‘‘drug holiday’’ condition. As an example of up-
regulated oncosuppressor miRNAs; miR-155 was over-expressed
during the scheduled follow up of the treatment in both cancer cell
lines while down-regulation of this miRNA has been reported in
breast cancer. The TSG role for miR-155 was suggested due to
decreasing cell proliferation and triggering the apoptosis [43].
As down-regulated oncosuppressor miRNAs, we can mention in
both cancerous cell lines the lower-expression of two members of
let-7 family, let-7f and let-7g. The expression of several members
of let-7 family including let-7f and let-7g, was previously reported
to be down-regulated in breast cancer samples with either lymph
node metastasis or distance metastases [43]. In addition, miR-27b
also showed down-regulation after treatment in all three analyzed
cell lines. MiR-27b is considered as a regulator of CYPB1 and acts
as a tumor suppressor that is suppressed in breast cancer [44].
As oncomiRs, several miRNAs were differentially expressed
after treatment (Table 2). Interestingly, the up-regulation of most
important oncomirs was detected in early passages after treatment
but down-regulation of the other oncomiRs mostly happened as a
late effect (Table 2). This finding suggests that the up-regulation of
oncomiRs occurred as an early response to the therapy and it
changed over the late follow up passages. However, down-
regulation of oncomiRs as a positive effect of the treatment was
mostly found in late follow up passages and sowed more stability.
These late changes might be the consequence of dysregulation of
some upstream regulatory genes/miRNAs.
From oncomiR group, miR-21 has been reported as a potential
oncogene which promotes cell survival and proliferation [45]. In
breast cancer, miR-21 is overexpressed [43] and by targeting
multiple tumor suppressor genes, such as PTEN, PDCD4, TPM1,
and MASPIN has been implicated in the acquisition of invasiveness
and in promoting tumor metastatic properties in breast cancer
[46]. Moreover, miR-21 overexpression has been associated with
an advanced clinical stage and lymph node metastasis [47].
Interestingly, miR-21 was significantly down-regulated in both
MDA-MB231 and SKBR3 (P,0.001) after treatment. As another
important example, miR-27a plays an important role in breast
cancer by suppressing the expression of the transcription factors
ZBTB10/RINZF, and subsequently increasing several angiogenic
molecules, such as Survivin, VEGF and VEGFR1 [48]. A previous
report indicated over-expression of the miR-27a in breast cancer
[49]. Our results demonstrated that DAC treatment can
significantly suppress miR-27a expression.
Protein expression profiling
Proteins from the three selected cell lines were analyzed by 2D
gel electrophoresis. We could detect a total of 27 intersection
significantly up/down-regulated proteins (4 in HB2, 8 in MDA-
MB231 and 15 in SKBR3 cell lines) (Fig. 4A; Dataset S4).
Principal component analysis (PCA) showed similarity between
different treatment passages and in a dendrograms, differentially
expressed proteins clustered in different groups based on their
expression profile (Fig. 4A). In the control cell line (HB2), the
number of differentially expressed proteins was lower than in the
other two cancerous cell lines. The dendrogram of HB2 revealed
two clusters and these two clusters revealed approximately the
same expression level compared to the untreated cells. In MDA-
MB231 (a highly aggressive cancerous line), proteins whose
expression changed significantly, were categorized into two
clusters. One cluster showed fluctuating up-regulation along the
passages while the other returned to the level of untreated cells.
Protein expression profiles in SKBR3 (non- aggressive cancerous
line) were divided into three clusters. Interestingly, all three
clusters ended with over-expression and are attributable to late
effect of treatment. The protein expression profiles in both
cancerous cell lines were related to long term effects of the
treatment and could help to better define treatment intervals. The
fold change, P value, theoretical pI and spot volumes are
summarized in Dataset S4.
In total, 18 candidate spots were excised and submitted to LC-
MS-MS analyses for the protein identification. Identified proteins,
their gene IDs, theoretical molecular weights (kDa), number of
identified peptides and the percentage of amino acid coverage are
shown in Table 3. In some excised spots, we identified a single
protein, in some others multiple isoforms, and yet in others we
observed several proteins in a single spot. In all instances where the
probability of correct determination was close to 100% (as
determined by Scaffold) we have checked the observed molecular
mass and pI value (according to spot position on the gel) with the
MS identification.
Notably, in the spot 1543 (SKBR3 cell line) we could identify
four different isoforms of 14-3-3 protein which were confirmed
with two different replicates referring to the same spot; their
calculated molecular masses or pI values deviated from the
Figure 3. Gene ontology analysis. a) Gene set analysis and GO enrichment score for union genes of three cell lines. If a functional group had an
enrichment score over 1, the functional category was over expressed. A value of 3 or higher corresponds to significant over expression (chi-square
test; P,0.05). b) Forest plot analysis shows up/down-regulated of HB2 union genes based on their ontology enrichment. c) Forest plot analysis of
MDA-MB231 union genes. d) Forest plot analysis of SKBR3 union genes.
doi:10.1371/journal.pone.0027355.g003
Pan-Omics Investigation of Demethylation Treatment
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27355Figure 4. Protein expression matrix. A) Proteomics analysis of three cell lines. (a1 – a3 left panel) Proteomic images of representative gels of the
three cell lines HB2, MDA-MB231 and SKBR3 with indicated spot positions excised for mass spectrometry analysis; spot picking performed from up/
down-regulated intersection proteins. (a1 – a3 middle panel) PCA analysis of intersection proteins from treated cells and follow up passages 1, 3, 5, 7
and 10 from three cell lines. (a1 – a3 right panel) Clustering and classification of significantly up/down-regulated proteins based on their profiles
throughout the passages. B) Crosstalk between 3-dimensional Omics. Prediction of the possible interactions and links between intersection genes,
miRNAs and proteins.
doi:10.1371/journal.pone.0027355.g004
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Cell line
No. of
proteins/
spot Spot no. Detected proteins
Gene
name
Gene
ID
Accession
No.
MW
(kDa)
No. of
detected
peptides
aa
coverage
(%) Comments
HB2 Two 1385 rho GDP-dissociation inhibitor 2 ARHGDIB 397 gi|56676393 23 4 27
ran-specific GTPase-activating protein RANGAP1 5905 gi|542991 23 3 15
Three 850 beta-tubulin TUBB1 81027 gi|2119276 49 5 14 Replica (a)
protein TRK-fused gene TFG 10342 gi|21361320 43 4 8
protein disulfide-isomerase P4HB 5034 gi|20070125 57 25 46 Replica (b)
Four 1044 F-actin-capping protein subunit alpha-1
F-actin-capping protein subunit alpha-2
CAPZA1
CAPZA2
829
830
gi|5453597
gi|5453599
33 7 36 Two subunits
were detected
in replica (a)
eukaryotic translation initiation factor 3
subunit I
EIF3I 8668 gi|4503513 37 9 28 Replica (b)
zinc-alpha-2-glycoprotein AZGP1 563 gi|4502337 34 3 7
annexin A2 isoform 2 ANXA2 302 gi|4757756 39 3 3
MDA-MB231 One 1536 S-phase kinase-associated protein 1 SKP1 6500 gi|25777713 19 2 10
1622 peroxiredoxin 5 PRDX5 25824 gi|6912238 22 4 21
Two 953 T-complex protein 1 subunit
zeta isoform a
T-complex protein 1 subunit
gamma isoform a
CCT7
CCT3
10574
7203
gi|4502643
gi|63162572
58 10 19 Two subunits
were detected
in replica
stress-induced-phosphoprotein 1 STI1 10963 gi|5803181 6 6 12
1076 voltage-dependent anion channel 2 VDAC2 7417 gi|48146045 30 7 25
Calponin 2 CNN2 1265 gi|4758018 34 5 17
Four 1293 tumor protein D54 TPD52L2 7165 gi|40805860 22 8 47 Replica (a)
rho GDP dissociation inhibitor (GDI) ARHGDIA 396 gi|36038 23 6
Galectin-7 LGALS7 3963 gi|3891470 28 3
glutathione S-Transferase M2-3 GSTM2 2946 gi|5822511 26 5 21 Replica (b)
1486 manganese superoxide dismutase SOD2 6648 gi|34707 25 5 12
phosphatidylethanolamine-binding
protein 1
PEBP1 5037 gi|4505621 21 5 30
regulator of G-protein signaling 10 RGS10 6001 gi|18266777 20 4 12
transgelin-2 TAGLN2 8407 gi|4507357 22 3 10
SKBR3 One 1121 RCN3 reticulocalbin 3 RCN3 57333 gi|28626510 7 37 21
1219 retinoblastoma binding protein 7
(histone-binding protein RBBP7)
RBBP7 5931 gi|4506439 48 4 7
1470 ribosomal protein L7 RPL7 6129 gi|35903 29 3 17
1543 14-3-3 protein YWHAQ
YWHAB
YWHAZ
YWHAH
10971
7529
7534
7533
gi|5803227
gi|4507949
gi|4507953
gi|4507951
28 6 23 Four different
isoforms were
detected and
confirmed in
both replicates
1590 chromobox protein homolog 1 CBX1 10951 gi|5803076 21 2 10
1633 glyoxalase-I GLO1 2739 gi|5020074 21 5 22
2162 canopy homolog 2 isoform 1 precursor CNPY2 10330 gi|7657176 21 2 14
Two 1727 GTP-binding protein SAR1a SAR1A 56681 gi|9910542 22 3 17
proteasome subunit beta type-2 PSMB2 5690 gi|4506195 23 3 19
Four 960 spliceosome RNA helicase BAT1 BAT1 7919 gi|4758112 49 13 32
26S proteasome non-ATPase regulatory
subunit 5
PSMD5 5711 gi|4826952 56 7 15
beta-tubulin TUBB1 81027 gi|2119276 49 5 14
protein disulfide-isomerase A6 PDIA6 10130 gi|5031973 48 5 15
(aa: amino acids).
doi:10.1371/journal.pone.0027355.t003
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highly conserved protein family, is a large family of 25–30 kDa
acidic proteins and has seven homologous isoforms in mammalian
cells which are involved in a variety of biological interactions, cell-
cycle progression, apoptosis, and mitogenic signaling, such as the
ATM-p53 pathway, suggesting their possible role in tumorigenesis
[50]. 14-3-3 theta is an adapter protein implicated in the
regulation of both general and specialized signaling pathways by
binding to a large number of partners, usually by recognition of a
phosphoserine or phosphothreonine motif.
Interestingly, five differentially expressed genes detected by
transcriptomic analysis were also identified by mass spectrometry
at the proteome level, which indicated similar expression trends at
both, the transcriptome and proteome (Dataset S4). The results
implicated that two of these five proteins (Sod2 and Pebp1) were
detected in one spot (SKBR3; 1486). These data support the mass
spectrometry results for those cases where more than one protein
species were detected within one single spot (Table 3).
Following the protein identification, the molecular function,
biological processes, and subcellular localization was categorized
using the PANTHER gene ontology database (http://pantherdb.
org) and ResNetH 7 (Mammal) database. The analyzed data
showed that 28 out of 41 detected proteins/isoforms in the three
analyzed cell lines are linked to neoplasms, metastasis or
carcinogenesis (Dataset S4).
Integrative, pan-omics
Possible crosstalk between all identified union genes, miRNAs
and proteins with a reported role to carcinogenesis, was
investigated in this study. In total, 11 genes, 11 miRNAs and 10
proteins showed interesting regulatory interactions with each other
(Fig. 4B).
Dysregulation of metastasis related genes/miRNAs. In
order to screen the direct effect of the DAC treatment on tumor
metastasis, we analyzed the expression profile of PDCD4, DHFR,
and HOXD10, three of the most promising genes implicated in the
metastatic process [49,51]. Among these metastasis related TSGs,
only PDCD4 was altered by the scheduled treatment and was
significantly up-regulated in the highly aggressive cell line (MDA-
MB231) and significantly down-regulated in the non-aggressive
cell line (SKBR3) (Fig. 5A). Two miRNAs (miR-21 and miR-183),
have complementary sites for the 39-UTR of PDCD4 and are
considered to be possible suppressors of this gene [51,52].
Interestingly, the co-expression analysis revealed down-regulation
of miR-21 in the MDA-MB231, which was inversely correlated to
PDCD4 in the same cell line (P,0.001) (Fig. 5-a1). This finding is
in line with previous reports suggesting miR-21 as a potential
down-regulator element for PDCD4 gene [51,52]. However, miR-
183 did not show any significant correlation with the expression of
PDCD4 in either of the two breast cancer cell lines (Fig. 5A), which
is in contradiction with previous report [53]. This suggests that
miR-21 (rather than the miR-183) is responsible for regulation of
PDCD4.
Furthermore, CXCR4 as one of 19 known human G protein–
coupled chemokine receptors is specifically implicated in cancer
metastasis and HIV-1 infection [54]. CXCR4 has been associated
with more than 23 cancer types promoting the metastasis,
angiogenesis, tumor growth and poor prognosis of patients.
Over-expression of CXCR4 has also been shown in ,10% of the
tumors [55]. There is the possibility of using CXCR4 as a
therapeutic target against solid tumors [56]. Interestingly, CXCR4
was significantly down-regulated in all scheduled follow-ups after
demethylation treatment in MDA-MB231 (Fig. 5-a1). This finding
suggests that down-regulation of CXCR4 can be a secondary
response to the demethylation of other upstream regulatory
elements in the aggressive form of breast cancer.
Taken together, over-expression of PDCD4, inhibitor of cell
proliferation and invasion through increasing the apoptosis, and
conversely down-regulation of CXCR4, activator of cell prolifer-
ation and invasion, after treatment with DAC, suggests reduction
of the invasion and metastasis for the highly aggressive subtype of
breast cancer.
Suppression of ERBB2/HER2 receptor in the non-
aggressive breast cancer subtype after DAC treatment.
The estrogen receptor (ER), progesterone receptor (PR) and
ERBB2/HER2 markers are used as prognosis indicators in breast
cancer to stratify patients for appropriately targeted therapies [57].
After DAC treatment, there were no significant changes in
hormonal receptor expression status (ESR1, ESR2, PGR and
ERBB2) for HB2 (breast epithelial cell line) and MDA-MB231
(triple hormonal negative cell line). In SKBR3 (ERBB2/HER2
positive cell line), ERBB2 showed a steady down-regulation after
treatment (Fig. 5B). The ERBB2 is a proto-oncogene that encodes
a member of the epidermal growth factor (EGF) receptor family of
tyrosine kinases. Amplification and/or over-expression of this gene
have been reported in numerous cancers, including breast and
ovarian tumors [58]. To understand the molecular mechanism of
ERBB2 down-regulation, we analyzed the expression profile of
negative upstream regulators (Fig. 5-b1). From 21 candidates, two
genes (BRCA1 and MYC) and a miRNA (miR-125b) showed
significant up-regulation in the treated cells. From these three
negative regulators, expression of two (MYC and miR-125b) were
inversely correlated with ERBB2 expression (P,0.001) (Fig. 5-b2).
MiR-125b, which was previously reported to be down-regulated in
breast cancer [43], is involved in the regulation of ERBB2 and
ERBB3, impairing the downstream signaling pathway and the
ability of the cells to grow and invade [59]. MiR-125b was
significantly over-expressed as early and late effects only in
SKBR3 (Table 2). Interestingly, in this regard we could identify a
positive upstream regulator protein (Pdia6 protein) by mass
spectrometry, which presented a significant correlation with
ERBB2 down-regulation (P,0.05) (Fig. 5-b3). Pdia6 is an
activator for ERBB2 which can contribute to the cell
proliferation and breast neoplasm [60].
Dysregulation of drug tolerance genes/miRNAs. The
relatively rapid acquisition of resistance to cancer drugs remains a
key obstacle for a successful cancer therapy [61]. Cancer-initiating
cells have been proposed as potential culprits because of their
capacity to escape from the drug effects by becoming quiescent
[62]. To get insights into the underlying mechanisms of drug
resistance against DAC, we checked the expression status of more
than 40 candidate genes suggested by the pathway analysis that
are involved in a variety of resistance mechanisms. From these
candidate genes/proteins, 12 genes detected by differential
transcriptomics (IL6, TGFB1, VEGFA, SERPINB5, FGF2, SFN,
ERBB2, RAD51, CSF2, COL18A1, MDK and TNFSF10) and four
proteins detected proteomically (P4hb, Sod2, Arhgdia and Glo1)
were mostly up-regulated after DAC treatment (Table 2; Fig. 6).
At the protein expression level, significant alterations over the
scheduled follow ups were found for the P4hb protein in the HB2
cells, Sod2 and Arhgdia proteins in MDA-MB231 cells, and for
the Glo1 protein in SKBR3 cells (Fig. 6).
The miRNAs expression alteration in response to the
chemotherapy was previously studied and showed that Let-7i,
miR-181a, -221, -27b, -34a, -424, -638 and -768 were up-
regulated and miR-17, -21 and -28 were down-regulated after
exposure to several drugs [63]. Our analysis of the genome-wide
effects of DAC on cellular miRNAs, implicated significant down-
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cancerous cell lines and miR-17 in the non-aggressive cell line
(Table 2; Dataset S5). At least three miRNA families were up-
regulated: MiR-638 in all three cell lines, miR-34a in the highly
aggressive line, miR-424 in the non-aggressive line, in a
concordance with previous reports [63]. Other miRNAs were
down-regulated upon treatment with DAC in all cell lines (miR-
181a and -27b). In some instances, Let-7i and miR-221 presented
different responses than reported in the literature [63]. In
conclusion, most of the miRNAs with a role in drug resistance
were down-regulated (Table 2) which suggests a lower resistance
control of miRNAs after drug treatment.
Prominent regulatory role of miR-24 on the methylated
P16-INK4A gene in the non-aggressive breast cancer
subtype. P16-INK4A acts as an inhibitor of CDK4 kinase and
in cooperation with TP53 has a regulatory role for cell cycle G1
control. This gene is frequently silenced (through hypermethy-
lation of specific CpG islands in the promoter, mutation,
Figure 5. Dysregulation of important indicators of metastasis, prognosis and hormone receptors after treatment. A) Regulation of
PDCD4 and CXCR4 genes as important indicators of metastasis and prognosis before and after treatment in two studied cancerous cell lines. a1-2)
Expression profiles of PDCD4 and CXCR4 genes and regulatory microRNAs in MDA-MB231 and SKBR3 cell lines, respectively. a3) Pathway analysis
predicts the role of PDCD4 and CXCR4 in cancerogenesis and shows the upstream regulatory miRNAs. B) Mechanism of ERBB2 receptor down-
regulation in SKBR3 (non-aggressive breast cancer cell line). b1) Pathway analysis shows negative upstream regulators of ERBB2 gene and PDIA6 as an
example of positive regulators. b2) Expression profiles of ERBB2 and some negative regulators (BRCA1, MYC and miR-125b) that demonstrated
significant changes during treatment. b3) Expression profile of Pdia6 protein as a positive regulator of ERBB2 that is detected by proteomics analysis.
doi:10.1371/journal.pone.0027355.g005
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nonendocrine tumors [64], and this alteration may be predictive
of the recurrence, tumor growth, or aggressiveness [36]. Our
previous study showed significant promoter hypermethylation of
CDKN2A (P16-INK4A) gene in breast cancer tissues as well as in the
circulating cell free DNA (cff DNA) of patients [26,65]. In the
present study, P16-INK4A was not transcriptionally active and after
treatment withDACshowed no significant change in the expression
level in both cancer cell lines (Fig. 7a-b). It is reported that P16-
INK4A has homozygote deletion (c.1_471 del 471) in MDA-MB231
cell line [66]. Our data from full gene sequencing also confirmed
homozygote deletion in this cell line (data not shown).
SKBR3 cell line showed significant reduction in the methylation
proportion of the P16-INK4A promoter (P,0.05) after treatment
with DAC (Fig. 7c). In spite of CDKN2A hypomethylation induced
by DAC, there wasn’t any change in the expression level of the
gene (Fig. 7b). In order to screen the possible mutation in the P16-
INK4A, we performed full gene sequencing on the promoter
region, 59UTR, three exons including exon/intron boundaries
(exon 1-3) and 39UTR. The sequencing result showed two
different mutations/polymorphisms, a heterozygote transition
mutation in 59UTR (c. 81 G.A) and a homozygote transversion
mutation in 39UTR (c.771 G.C) of the gene (Fig. 7d). These two
mutations/polymorphisms were located in the UTR part of the
Figure 6. Drug tolerance after treatment with DAC. Candidate genes and proteins that are involved in drug tolerance with significant
expression changes after treatment (A). Cell lines: HB2 (B), MDA-MB231 (C) and SKBR3 (D). Expression profiles of 12 candidate genes (TGFB1, VEGFA,
SERPINB5, FGF2, SFN, ERBB2, RAD51, CSF2, COL18A1, MDK, TNFSF10 and IL6) (b1, c1 and d1). Expression profiles of candidate proteins: P4hb (b2), Sod2
(c2), Arhgdia (c3) and Glo1 (d2).
doi:10.1371/journal.pone.0027355.g006
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SKBR3.
Further investigation demonstrated steady up-regulation of
miR-24 in SKBR3 after treatment and at all follow-up passages
(Fig. 7f). MiR-24 has intriguing complementarities to 39-UTRs
and controlling region (CR) of the P16-INK4A and can suppress
the gene (Fig. 7e) [67]. Two found mutations/polymorphisms are
not located in the complementary site of the miR-24, and
therefore they cannot be responsible for the change of the binding
affinity of the miR-24 to the gene (Fig. 7g). The expression of miR-
24 showed significant inverse correlation to P16-INK4A which
might provide an explanation for P16-INK4A shut down in the
non-aggressive cell line. These findings highlight the specific role
of the epigenetic regulation of TSGs during carcinogenesis.
Inverse correlation of up-regulated miR-29b as a
methylation suppressor, with expression of DNMT3A in
the non-aggressive cell line. The miRNA (miR)-29 family
(29a, 29b, and 29c) has intriguing complementarities to
39-UTRs of DNA methyltransferase (DNMT)3A and -3B (de
novo methyltransferases), two key enzymes involved in DNA
methylation, that are frequently up-regulated in solid tumors and
associated with the poor prognosis. In lung squamous cell
carcinomas, elevated Dnmt1 expression has been reported as a
poor prognosis factor. Moreover, elevated expressions of both
Dnmt1 and Dnmt3B have been shown to be correlated with
hypermethylation of TSG promoters [68]. It was shown that
expression of miR-29s, especially miR-29b, is directly targeting
both DNMT3A and -3B and is inversely correlated to their
expression in lung cancer tissues [69,70]. In the present study,
after demethylation treatment with DAC, the expression of miR-
29b was inversely correlated with DNMT3A expression in SKBR3
(Fig. 8). Additionally, in SKBR3 cell line with up-regulation of
miR-29b and steady down-regulation of DNMT3A, an almost 10
fold increase of number of the differentially expressed genes after
demethylation treatment was found compared to MDA-MB231
(Fig. 8e vs. Fig. 8c). The presented data highlight a prominent role
of Dnmt3A in the hypermethylation of promoters in the studied
breast cancer cell lines. This finding also suggests that a
combination of chemical demethylation treatment with DNMT
inhibitors (decitabine or azacitidine) with enforced expression of
Figure 7. Epigenetic regulation of P16-INK4A tumor suppressor gene. a) Expression profile of P16-INK4A in treated and untreated cell lines; in
two cancerous cell lines (MDA-MB231 and SKBR3) no expression was detected. b) Expression profile of P16-INK4A within all analyzed passages
according to the normalized Ct values (DCt). c) Methylation proportion of informative CpG sites of P16-INK4A in SKBR3 cell line. d) Full gene
sequencing of P16-INK4A revealed a heterozygote transition mutation in 59UTR and a homozygote transversion mutation in 39UTR of the gene. e)
Pathway analysis predicts the role of has-miR-24 (MIRN24) as a down-regulator of the P16-INK4A. f) Expression profile of has-miR-24 in the non-
aggressive breast cancerous cell line (SKBR3) versus control breast cell line (HB2). g) Comparison of miR-24 recognition site with the location of found
mutations in the mature P16-INK4A mRNA.
doi:10.1371/journal.pone.0027355.g007
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hypomethylation effects that may result in a better disease
response in breast cancer along with more robust gene re-
expressions especially for the epigenetically silenced TSGs.
To understand the molecular mechanism of miR-29b deregu-
lation, we analyzed the co-expression profiles of two important
upstream suppressors (miR-152 and miR-455) [71]. Both of miR-
29b suppressors, miR-152 and miR-455, were over-expressed in
MDA-MB231 cell line. In SKBR3, along with the over-expression
of miR-29b, miR-455 was also up-regulated whereas miR-152 did
not show any significant change. These data suggest a prominent
inhibitory effect of miR-152 rather than miR-455 on the
regulation of miR-29b emphasizing the controlling effect of
miRNAs in certain types of cancer.
Conclusions
The aberrant DNA methylations of genes/miRNAs which are
involved in malignant phenotypes provide interesting targets for
chemotherapeutic intervention. To the best of our knowledge, the
study presented here is the first pan-omics approach to
synoptically identify epigenetic, transcriptome and proteome-wide
alterations after effective demethylation treatment with DAC in
the context of breast cancer.
The results of our synoptic pan-omics analysis provide a
comprehensive view of DAC treatment defined by stable or
transient early and late systematic effects in the model of cancer
specific changes. We investigated DAC targets in depth (e.g. genes,
miRNAs and proteins) and identified new pathways as well as
biological interactions at the molecular levels that may correlate
with particular steps in breast neoplasm including cell prolifera-
tion, cell/tissue invasion, oncogenesis, angiogenesis, apoptosis,
neoplasm metastasis and senescence.
In total, SKBR3 (non-aggressive breast cancer cell line) showed
more significant changes in the gene expression and proteomics
levels than MDA-MB231 (highly aggressive breast cancer cell line)
does. This finding highlights that the epigenetic treatment of
hypermethylation genes during carcinogenesis, might have a more
advantageous effect when cells are still less aggressive.
Additionally, along with the activation of several epigenetically
suppressed TSGs, we also showed significant down-regulation of
some important miRNAs with oncogenic functions in breast
cancer cell lines (e.g. miR-21) as well as over-expression of
some miRNAs with tumor suppressor functions (e.g. miR-155)
that highlights the potential of a miRNA-based therapy in
breast cancer. In the present study, there is a limitation of
lacking inclusion of a luminal cell line to be compared with two
studied basal like breast cancer subtypes MDA-MB231 (the triple
negative receptor subtype) and SKBR3 (the Her2-associated
subtype).
The presented approach might become a useful model for other
human solid tumor malignancies, alone or in combination with
other treatments such as enforced targeted therapies for miR-29b
and/or IL6 (IL6 or IL6 receptor antagonists).
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metastasis or carcinogenesis
N Heatmaps of significant up/down-regulated union miRNAs
N Expression level of important cancer related miRNAs using
qPCR
(PDF)
Dataset S4 Proteomic Profiles.
N Spot picking gels for significant up/down-regulated intersec-
tion proteins
N Expression profile of candidate spots within different treatment
passages
N Pathway analysis of proteins/isoforms in that are linked to
neoplasms, metastasis or carcinogenesis
N Expression profiles of five genes/proteins that were detected
similarly in both transcriptomic and proteomic analysis
(PDF)
Dataset S5 List of significantly up/down-regulated
genes/miRNAs as early or late effects of the treatment
in three cell lines.
(XLS)
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